Memphis is one of the oldest pharmaceutical and chemical companies in the Middle East and has been in the market since 1940.
The availability of over-the-counter (OTC) products is essential to improve the level of healthcare provided to patients.
The company is set to become a hub for mRNA technology for Africa and low- and middle-income countries, Rabie added.
Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.
Arab Drug is an Egyptian company engaged in the pharmaceutical sector.
The new plant was built on an area of 15,527 square meters and its investment is close to one billion Egyptian pounds last year.
Nile Pharma manufactures and markets pharmaceuticals.
Dr. George said that the sector’s exports achieved an increase of 200% compared to 2019 exports before the Coronavirus pandemic.
Following the recent releases, the country's strategic drug reserve rose to 6-12 months.
Pfizer Egypt team will share with the students of the Faculty of Pharmacy at FUE the latest expertise in the pharmaceutical market.
The company’s net profit after tax jumped to EGP 71.283 million in July-November from EGP 59.908 million the year before.
Accordingly, the company’s issued capital will increase to EGP 252.113 million from EGP 250 million.
The African market is promising for the sector's products during 2023, but some obstacles must be dealt with.
In June 2022, VACSERA settled debts of EGP 712.5 million for National Investment Bank, the report showed.
Celltrion Healthcare will handle the development, manufacturing and supply of Vegzelma and Hikma will handle the commercialization.
The minister discussed cooperation with the MSD company to provide the latest oncological treatments (immunotherapy) for breast cancer patients.
Moreover, exports of medical industries rose by 11.30% YoY during January-August 2022 to reach $69 million from $62 million.
Producing medicines locally would reduce the import bill, absorb pharmacy and science graduates, and provide medicine on time.
Under the partnership, the distribution of insulin to middle- and low-income countries—most of them in Africa—is expected to begin in 18 months.
Egypt has no shortage in medicinal drugs and that local companies fulfill 90 percent of needs.